MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Engitix
Attachments
Engitix – Rethinking Drug Discovery for Fibrosis and Cancer
Parents
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
*Industry: United Kingdom - UK (England, Scotland, Wales, Northern Ireland)
Children
2020: Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH
2020: The idea now is to combine Engitix’s extra-cellular matrix platform with Takeda’s experience in gastroenterology.
London, England, United Kingdom
Jumps
Takeda Pharmaceutical Company Ltd (NYSE:TAK)(OTCPK:TKPHF)